A Phase 2 interventional study of BIO101 and Placebo in Sarcopenia, Gait Disorders in Old Age and Muscle Weakness, sponsored by Biophytis. Completed at 22 sites in 2 countries. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2024-10-01.
Sponsored by Biophytis · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 187 studies in Sarcopenia with a site in United States — 37 open to participants now, 47 under way, 1 of them phase 3. Sarcopenia · United States.
Among the 187 studies in Sarcopenia with a site in United States, this one is the 7th largest by enrollment of the 146 interventional ones that give a count, is one of 15 that started in 2017, is one of 20 in phase 2, and was the 95th registered.
1,329 studies on the registry are indexed under Sarcopenia; 419 are open to participants now.
Browse Sarcopenia studies →37 of the 187 studies in Sarcopenia with a site in United States are open now. Recruiting first, the newest first:
Bettina Mittendorfer · Sites in United States
Ages 18–100 · Healthy volunteers
St. Jude Children's Research Hospital · Sites in United States
Ages 18+ · Healthy volunteers
Ohio State University · Sites in United States
Ages 18+
Kennesaw State University · Sites in United States
Ages 65–85 · Healthy volunteers
Health Discovery Labs · Sites in United States
Ages 18–85
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 247 Sarcopenia studies recruiting now, 153 (62%) set no upper age limit and 32 (13%) stop at 75 or younger; 9 take children under 18; 65 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
187 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 24 · Phase 3 3 · Phase 4 5
First in 1995; this study’s year is marked. 15 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 233 is above the median of 60 across 856 interventional studies indexed under Sarcopenia.
Median enrollment 40 across the 146 interventional studies, 70 across the 40 observational. Of the 126 that completed or were terminated, 43 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 187 have an industry lead sponsor. The 10 most frequent:
Biophytis is the lead sponsor of 4 studies on the registry; 1 is open to participants now.
Biophytis has 2 studies filed under Sarcopenia — fewer than ten, so there is no comparison to draw.
16 of the studies in Sarcopenia with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05422534Phase 3Vanderbilt University Medical CenterCoQ10 and Exercise for Mitochondrial Dysfunction in Advance Kidney Disease | 2027-06-20 |
| NCT06722508University of California, DavisExercise and Nutritional Prehabilitation for Head and Neck Cancer Patients | 2026-12 |
| NCT07029243University of California, San FranciscoPrehab and Creatine/Whey Supplementation in Frailty Among Patients With Cirrhosis | 2026-12 |
| NCT06628349Texas A&M UniversityPrandial Metabolic Phenotyping in Sarcopenic Older Adults Comparing Plant Based and Whey Based Protein | 2026-12 |
| NCT03998202Wake Forest University Health SciencesMyopenia and Mechanisms of Chemotherapy Toxicity in Older Adults With Colorectal Cancer | 2026-12-31 |
Add all 16 to your calendar (.ics) → With an account.
Among the 187 studies in Sarcopenia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main objective of the study is to evaluate the effect of two daily doses of BIO101 versus placebo on mobility function as measured by gait speed using the 400MW test. The absolute change from baseline in meters/second observed in each treatment group at 6 Month was compared to the placebo group. Due to the Covid pandemic >50% of data at endpoint was missing, which may have affected the ability of the study to deliver the expected results. Additionally, although the planned duration of treatment was 6 months, it was extended up to 9 months for some participants as a result of the pandemic.
The aim of this phase 2 double-blind, placebo-controlled, randomized interventional clinical trial (SARA-INT) is to evaluate the safety and efficacy of BIO-101 175 mg b.i.d. and 350 mg b.i.d. 9 months oral administration to participants suffering from age-related sarcopenia, including sarcopenic obesity, aged ≥65 years and at risk of mobility disability. There are 3-arms (2 doses versus placebo). This comparative clinical trial evaluated the effects up to 9 month treatment duration, based on the hypothesis that physical function of sarcopenic, older participants with an initial degree of mobility disability (SPPB) may be improved by BIO101.
Included participants were randomized in a 1:1:1 ratio, to one of the 3 arms of treatment in a blinded manner. The randomization was stratified by gender and by center. Based on absence of long-term toxicology data, the investigational drug exposure was initially capped at 6 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Clinical conditions:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo was taken orally, two capsules twice daily (BID), 12 hours apart, up to 9 months.
Drug: Placebo
BIO101 was taken orally, two capsules BID, 12 hours apart, up to 9 months.
Drug: BIO101
BIO101 was taken orally, two capsules BID, 12 hours apart, up to 9 months.
Drug: BIO101
Oral capsules
Also known as: 20 hydroxyecdysone (20E)
Oral capsules
Change From Baseline to 6 Months in Gait Speed for 400 Meter Walking (MW) Test
Gait speed was measured using the 400 MW test, which measured how long it took the participant to walk a distance of 400 meters. Missing data imputed using adjusted Bayesian Multiple Imputation (MI) methods for Non-Completers who failed to perform the Test feasibility and Multiple Imputation for participants who without data on on-Site visit. Data up to 9 months was used where 6 months data were unavailable for participants enrolled during the COVID-19 pandemic.
Time frame: Baseline and 6 Months
Change From Baseline to 6 Months in Short Form-36 (SF-36) 10 Item Physical Function Domain (PF-10) Sub-score
The Physical Function Domain (PF-10) of the SF-36 assesses an individual's perceived physical functioning and limitations in various activities. It consists of ten items that ask about a person's ability to perform different physical activities and tasks. Scores on the PF-10 range from 0 to 100 where 100 indicates no physical limitations. Missing data imputed using adjusted Bayesian MI methods. Data up to 9 month was used where 6 month data were unavailable for participants enrolled during the COVID-19 pandemic.
Time frame: Baseline and 6 Months
Change From Baseline to 6 Months in Handgrip Strength Test
Handgrip strength was a commonly used measure of upper body skeletal muscle function and had been widely used as a general indicator of frailty with predictive validity for both mortality and functional limitations. Participants were instructed to stand upright and with the dynamometer beside them but not against their body. Strength was measured three times for both hands. The highest value of all 3 attempts was kept for further analysis. Grip strength was measured in the dominant hand using a hydraulic grip strength dynamometer. Data up to month 9 was used where 6 month data were unavailable for participants enrolled during the COVID-19 pandemic.
Time frame: Baseline and 6 Months
Change From Baseline to 6 Months in Appendicular Lean Body Mass (ALM) Based on Dual-energy X-ray Absorptiometry (DEXA) Measurements
DEXA scans provided accurate measurements of body composition, recording fat and lean mass distribution throughout the entire body. Foundation of National Health Institute (FNIH) project report recommended ALM alone was used to measure gender-specific low muscle mass. Data up to month 9 was used where 6 month data were unavailable for participants enrolled during the COVID-19 pandemic.
Time frame: Baseline and 6 Months
Rate of Response for Completing 400 MW Test After 6 Months
A responder was defined as an improvement (increase) of 0.1 m/s or more in 400MW gait speed test compared to baseline. A non-responder was defined as a participant that was not a responder. Participants with a missing value at the visit and/or missing baseline value were considered as non-responders. Data up to month 9 was used where 6 month data were unavailable for participants enrolled during the COVID-19 pandemic.
Time frame: Baseline and 6 Months
Change From Baseline to 6 Months in Muscle Strength Based on Knee Extension
Isometric knee extension torque was measured with a knee extension dynamometer chair. The participants were positioned in an upright position, with straps to affix the hips to the chair and the ankle to a force or torque transducer at the knee angle of 90°. Lever arm length was recorded as the distance between the knee axis of rotation and the middle of the pad. Knee extension was measured using the maximum peak torque measurement Newton meter (Nm) for 60°/s, 90°/s and 180°/s for the tested leg (either right or left). The Knee extension torque was obtained either directly or by multiplying recorded peak force with the lever arm length. The assay with the highest torque output was taken for analyses. Data up to month 9 was used where 6 month data were unavailable for participants enrolled during the COVID-19 pandemic.
Time frame: Baseline and 6 Months
Change From Baseline to 6 Months in Time for Five Chair Stands as Part of the Short Physical Performance Battery (SPPB) Assessment
The SPPB was a series of tests designed to examine physical movements. The chair stands tests involved standing from a chair a number of times to test leg strength. Each performance measures were assigned a score ranging from 0 to 4, with 4 indicating the highest level of performance and 0 the inability to complete the test. The time to complete the task was recorded. The time required to perform five chair stands was scored as follows: ≥ 16.70 sec = 1; 13.70 to 16.69 sec = 2; 11.20 to 13.69 sec = 3; ≤ 11.19 = 4. A score of 0 was assigned to participants unable to perform the task. A summary score ranging from 0 (worst performers) to 12 (best performers) was calculated by adding sub scores from the chair stands test. Data up to month 9 was used where 6 month data were unavailable for participants enrolled during the COVID-19 pandemic.
Time frame: Baseline and 6 Months
Change From Baseline to 6 Months in Distance in the 6-Minute Walk Test (6MWT)
The 6MWT was a test for functional exercise capacity and involved measuring the distance a participant could cover within the allotted time of 6 minutes. Data up to month 9 was used where 6 month data were unavailable for participants enrolled during the COVID-19 pandemic.
Time frame: Baseline and 6 Months
Change From Baseline to 6 Months in Pepper Assessment Tool for Disability (PAT-D) for Obese Participants
The PAT-D was a disability questionnaire which asked respondents how much difficulty they had with a range of activities with functioning. PAT-D scores range from 1 (worst) to 5 (best). Data up to month 9 was used where 6 month data were unavailable for participants enrolled during the COVID-19 pandemic.
Time frame: Baseline and 6 Months
Change From Baseline to 6 Months in SPPB Total Score
The SPPB was a series of tests designed to examine physical movements. Results of the SPPB included total gait speed score, total balance test score, and total chair stand score. The first tests examined balance (without the assistance of a cane or walker) with the feet in three different orientations, the second test examined gait speed, and the third tests involved standing from a Chair a number of times to test leg strength. A score of 0 was assigned to participants unable to perform the task. A summary score ranging from 0 (worst performers) to 12 (best performers) was calculated by adding sub scores from the walking speed, chair stands and balance tests. Data up to month 9 was used where 6 month data were unavailable for participants enrolled during the COVID-19 pandemic.
Time frame: Baseline and 6 Months
Change From Baseline to 6 Months in Sarcopenia Quality of Life (SarQoL) Auto-Evaluation Questionnaire
The SarQoL was a sarcopenia-specific, self-administered, quality of life questionnaire designed for community-dwelling elderly study participants aged 65 years and older. The questionnaire contained 22 questions, which took approximately 10 minutes to complete. The questionnaire covered 7 domains: physical and mental health; locomotion; body composition; functionality; activities of daily living; leisure activities; and fears. Most questions are answered on a 4 point Likert scale. The total scoring of the SarQoL questionnaire ranges from 0 (worst imaginable health) to 100 (best imaginable health). A higher score reflected a higher quality of life. Data up to month 9 was used where 6 month data were unavailable for participants enrolled during the COVID-19 pandemic.
Time frame: Baseline and 6 Months
Change From Baseline to 6 Months in Stair Climb Power Test (SCPT)
The SCPT measured the ability to ascend and descend stairs and tests lower body strength and balance and measures time (in seconds) taken to ascend and descend a flight of stairs (10 steps with a 20 cm step height; a handrail was recommended). Step heights should have been suitable (between 16 and 20 cm). Data up to month 9 was used where 6 month data were unavailable for participants enrolled during the COVID-19 pandemic.
Time frame: Baseline and 6 Months
Participants were enrolled from 19 centers in the United States and 3 centers in Belgium.
| Milestone | Placebo | 175mg BIO101 | 350mg BIO101 |
|---|---|---|---|
| Started | 81 | 76 | 76 |
| Completed | 70 | 64 | 69 |
| Not completed | 11 | 12 | 7 |
| Withdrew: Adverse event | 4 | 6 | 1 |
| Withdrew: Death | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 1 | 2 | 0 |
| Withdrew: Pi decision | 1 | 0 | 0 |
| Withdrew: Withdrew consent | 4 | 2 | 2 |
| Withdrew: Withdraw due to the covid-19 outbreak | 1 | 0 | 1 |
| Withdrew: Other | 0 | 2 | 2 |
Gait speed was measured using the 400 MW test, which measured how long it took the participant to walk a distance of 400 meters. Missing data imputed using adjusted Bayesian Multiple Imputation (MI) methods for Non-Completers who failed to perform the Test feasibility and Multiple Imputation for participants who without data on on-Site visit. Data up to 9 months was used where 6 months data were unavailable for participants enrolled during the COVID-19 pandemic.
| Meter/Second (m/s) | Placebo | 175mg BIO101 | 350mg BIO101 |
|---|---|---|---|
| Gait Speed based on Mixed Effect Model | 0.0093 (-0.0369 to 0.0556) | 0.0457 (-0.0014 to 0.0927) | 0.0478 (0.0050 to 0.0907) |
| Gait Speed Based on Adjusted Bayesian Imputation | -0.2886 (-0.3641 to -0.2132) | -0.2543 (-0.3347 to -0.1738) | -0.2014 (-0.2790 to -0.1238) |
| MI + Adjusted Bayesian Imputation | -0.0188 (-0.0743 to 0.0366) | -0.0066 (-0.0547 to 0.0415) | 0.0500 (-0.0013 to 0.1013) |
The Physical Function Domain (PF-10) of the SF-36 assesses an individual's perceived physical functioning and limitations in various activities. It consists of ten items that ask about a person's ability to perform different physical activities and tasks. Scores on the PF-10 range from 0 to 100 where 100 indicates no physical limitations. Missing data imputed using adjusted Bayesian MI methods. Data up to 9 month was used where 6 month data were unavailable for participants enrolled during the COVID-19 pandemic.
| score on a scale | Placebo | 175mg BIO101 | 350mg BIO101 |
|---|---|---|---|
| Analysis based on Mixed Effect Model for MMRM | 7.3 (2.4 to 12.3) | 7.1 (1.9 to 12.3) | 7.1 (2.2 to 12.1) |
| Based on Adjusted Bayesian Imputation | 1.4 (-4.8 to 7.6) | 4.0 (-2.1 to 10.1) | 4.1 (-1.7 to 9.8) |
Handgrip strength was a commonly used measure of upper body skeletal muscle function and had been widely used as a general indicator of frailty with predictive validity for both mortality and functional limitations. Participants were instructed to stand upright and with the dynamometer beside them but not against their body. Strength was measured three times for both hands. The highest value of all 3 attempts was kept for further analysis. Grip strength was measured in the dominant hand using a hydraulic grip strength dynamometer. Data up to month 9 was used where 6 month data were unavailable for participants enrolled during the COVID-19 pandemic.
| kilograms (Kg) | Placebo | 175mg BIO101 | 350mg BIO101 |
|---|---|---|---|
| Handgrip strength Test at Month 6 (dominant hand) | -0.709 (-2.902 to 1.484) | -1.601 (-3.935 to 0.733) | 0.590 (-1.533 to 2.712) |
| Handgrip strength test at month 6 (Left hand) | -0.860 (-2.852 to 1.131) | -1.597 (-3.766 to 0.573) | 0.319 (-1.626 to 2.264) |
| Handgrip strength test at month 6 (Right hand) | -0.842 (-3.098 to 1.414) | -1.664 (-3.993 to 0.665) | 0.865 (-1.262 to 2.992) |
| Based on Multiple Imputation (dominant hand) | 0.145 (-2.270 to 2.561) | 0.297 (-2.194 to 2.788) | 0.663 (-1.822 to 3.148) |
DEXA scans provided accurate measurements of body composition, recording fat and lean mass distribution throughout the entire body. Foundation of National Health Institute (FNIH) project report recommended ALM alone was used to measure gender-specific low muscle mass. Data up to month 9 was used where 6 month data were unavailable for participants enrolled during the COVID-19 pandemic.
| Kg | Placebo | 175mg BIO101 | 350mg BIO101 |
|---|---|---|---|
| Change From Baseline to 6 Months in Appendicular Lean Body Mass (ALM) Based on Dual-energy X-ray Absorptiometry (DEXA) Measurements | -0.276 (-0.911 to 0.359) | -0.283 (-0.944 to 0.378) | 0.068 (-0.496 to 0.632) |
A responder was defined as an improvement (increase) of 0.1 m/s or more in 400MW gait speed test compared to baseline. A non-responder was defined as a participant that was not a responder. Participants with a missing value at the visit and/or missing baseline value were considered as non-responders. Data up to month 9 was used where 6 month data were unavailable for participants enrolled during the COVID-19 pandemic.
| Participants | Placebo | 175mg BIO101 | 350mg BIO101 |
|---|---|---|---|
| Responder | 4 | 9 | 11 |
| Non-responder | 77 | 66 | 65 |
Isometric knee extension torque was measured with a knee extension dynamometer chair. The participants were positioned in an upright position, with straps to affix the hips to the chair and the ankle to a force or torque transducer at the knee angle of 90°. Lever arm length was recorded as the distance between the knee axis of rotation and the middle of the pad. Knee extension was measured using the maximum peak torque measurement Newton meter (Nm) for 60°/s, 90°/s and 180°/s for the tested leg (either right or left). The Knee extension torque was obtained either directly or by multiplying recorded peak force with the lever arm length. The assay with the highest torque output was taken for analyses. Data up to month 9 was used where 6 month data were unavailable for participants enrolled during the COVID-19 pandemic.
| Newton meter (Nm) | Placebo | 175mg BIO101 | 350mg BIO101 |
|---|---|---|---|
| Change From Baseline to 6 Months in Muscle Strength Based on Knee Extension | 0.484 (-18.088 to 19.056) | -1.092 (-21.833 to 19.649) | -4.515 (-17.889 to 8.858) |
The SPPB was a series of tests designed to examine physical movements. The chair stands tests involved standing from a chair a number of times to test leg strength. Each performance measures were assigned a score ranging from 0 to 4, with 4 indicating the highest level of performance and 0 the inability to complete the test. The time to complete the task was recorded. The time required to perform five chair stands was scored as follows: ≥ 16.70 sec = 1; 13.70 to 16.69 sec = 2; 11.20 to 13.69 sec = 3; ≤ 11.19 = 4. A score of 0 was assigned to participants unable to perform the task. A summary score ranging from 0 (worst performers) to 12 (best performers) was calculated by adding sub scores from the chair stands test. Data up to month 9 was used where 6 month data were unavailable for participants enrolled during the COVID-19 pandemic.
| Seconds | Placebo | 175mg BIO101 | 350mg BIO101 |
|---|---|---|---|
| Change From Baseline to 6 Months in Time for Five Chair Stands as Part of the Short Physical Performance Battery (SPPB) Assessment | -3.857 (-6.024 to -1.690) | -2.572 (-4.721 to -0.422) | -1.206 (-3.135 to 0.724) |
The 6MWT was a test for functional exercise capacity and involved measuring the distance a participant could cover within the allotted time of 6 minutes. Data up to month 9 was used where 6 month data were unavailable for participants enrolled during the COVID-19 pandemic.
| Meters | Placebo | 175mg BIO101 | 350mg BIO101 |
|---|---|---|---|
| Change From Baseline to 6 Months in Distance in the 6-Minute Walk Test (6MWT) | -9.879 (-37.089 to 17.330) | -7.166 (-36.559 to 22.228) | 15.728 (-10.981 to 42.436) |
The PAT-D was a disability questionnaire which asked respondents how much difficulty they had with a range of activities with functioning. PAT-D scores range from 1 (worst) to 5 (best). Data up to month 9 was used where 6 month data were unavailable for participants enrolled during the COVID-19 pandemic.
| score on a scale | Placebo | 175mg BIO101 | 350mg BIO101 |
|---|---|---|---|
| Change From Baseline to 6 Months in Pepper Assessment Tool for Disability (PAT-D) for Obese Participants | -0.27 (-0.42 to -0.13) | -0.08 (-0.24 to 0.08) | -0.17 (-0.31 to -0.03) |
The SPPB was a series of tests designed to examine physical movements. Results of the SPPB included total gait speed score, total balance test score, and total chair stand score. The first tests examined balance (without the assistance of a cane or walker) with the feet in three different orientations, the second test examined gait speed, and the third tests involved standing from a Chair a number of times to test leg strength. A score of 0 was assigned to participants unable to perform the task. A summary score ranging from 0 (worst performers) to 12 (best performers) was calculated by adding sub scores from the walking speed, chair stands and balance tests. Data up to month 9 was used where 6 month data were unavailable for participants enrolled during the COVID-19 pandemic.
| score on a scale | Placebo | 175mg BIO101 | 350mg BIO101 |
|---|---|---|---|
| Change From Baseline to 6 Months in SPPB Total Score | 1.1 (0.5 to 1.6) | 1.00 (0.4 to 1.5) | 0.9 (0.3 to 1.5) |
The SarQoL was a sarcopenia-specific, self-administered, quality of life questionnaire designed for community-dwelling elderly study participants aged 65 years and older. The questionnaire contained 22 questions, which took approximately 10 minutes to complete. The questionnaire covered 7 domains: physical and mental health; locomotion; body composition; functionality; activities of daily living; leisure activities; and fears. Most questions are answered on a 4 point Likert scale. The total scoring of the SarQoL questionnaire ranges from 0 (worst imaginable health) to 100 (best imaginable health). A higher score reflected a higher quality of life. Data up to month 9 was used where 6 month data were unavailable for participants enrolled during the COVID-19 pandemic.
| score on a scale | Placebo | 175mg BIO101 | 350mg BIO101 |
|---|---|---|---|
| Change From Baseline to 6 Months in Sarcopenia Quality of Life (SarQoL) Auto-Evaluation Questionnaire | 8.05 (4.95 to 11.14) | 5.60 (2.43 to 8.78) | 5.83 (2.79 to 8.87) |
The SCPT measured the ability to ascend and descend stairs and tests lower body strength and balance and measures time (in seconds) taken to ascend and descend a flight of stairs (10 steps with a 20 cm step height; a handrail was recommended). Step heights should have been suitable (between 16 and 20 cm). Data up to month 9 was used where 6 month data were unavailable for participants enrolled during the COVID-19 pandemic.
| Seconds | Placebo | 175mg BIO101 | 350mg BIO101 |
|---|---|---|---|
| Change From Baseline to 6 Months in Stair Climb Power Test (SCPT) | 39.9 (-46.4 to 126.3) | 32.4 (-65.4 to 130.3) | 88.5 (5.1 to 171.8) |
Collected over Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 1/81 (1.2%) | 10/81 (12.3%) | 48/81 (59.3%) |
| 175mg BIO101 | 0/75 (0%) | 10/75 (13.3%) | 45/75 (60%) |
| 350mg BIO101 | 1/74 (1.4%) | 4/74 (5.4%) | 38/74 (51.4%) |
| Event | Placebo | 175mg BIO101 | 350mg BIO101 |
|---|---|---|---|
| Partial bowel obstructionGastrointestinal disorders | 0/81 | 0/75 | 1/74 |
| Orthostatic hypotensionVascular disorders | 0/81 | 0/75 | 1/74 |
| Coronavirus infectionInfections and infestations | 0/81 | 0/75 | 1/74 |
| Chest painMusculoskeletal and connective tissue disorders | 0/81 | 0/75 | 1/74 |
| Ischemic strokeCardiac disorders | 0/81 | 1/75 | 0/74 |
| Recurrent cardiac decompensationCardiac disorders | 0/81 | 1/75 | 0/74 |
| Unstable anginaCardiac disorders | 0/81 | 1/75 | 0/74 |
| ToothacheGastrointestinal disorders | 0/81 | 1/75 | 0/74 |
| Cellulitis of legInfections and infestations | 0/81 | 1/75 | 0/74 |
| Fracture of intertrochanteric section of femur, closedInjury, poisoning and procedural complications | 0/81 | 1/75 | 0/74 |
| Event | Placebo | 175mg BIO101 | 350mg BIO101 |
|---|---|---|---|
| FallInjury, poisoning and procedural complications | 4/81 | 2/75 | 3/74 |
| DiarrheaGastrointestinal disorders | 0/81 | 3/75 | 1/74 |
| Urinary tract infectionRenal and urinary disorders | 0/81 | 3/75 | 0/74 |
| ConstipationGastrointestinal disorders | 3/81 | 0/75 | 1/74 |
| NauseaGastrointestinal disorders | 0/81 | 2/75 | 2/74 |
| ArthritisMusculoskeletal and connective tissue disorders | 0/81 | 0/75 | 2/74 |
| FallMusculoskeletal and connective tissue disorders | 1/81 | 0/75 | 2/74 |
| BronchitisRespiratory, thoracic and mediastinal disorders | 0/81 | 0/75 | 2/74 |
| FluInfections and infestations | 0/81 | 2/75 | 0/74 |
| Myalgia of lower extremitiesMusculoskeletal and connective tissue disorders | 0/81 | 2/75 | 0/74 |
One participant randomized but not treated with 175 mg BIO101.
| Age, Continuous(Years) | Placebo | 175mg BIO101 | 350mg BIO101 | Total |
|---|---|---|---|---|
| Mean | 75.5 ± 7.12 | 76.2 ± 7.10 | 76.3 ± 6.38 | 76.0 ± 6.86 |
| Sex: Female, Male(Participants) | Placebo | 175mg BIO101 | 350mg BIO101 | Total |
|---|---|---|---|---|
| Female | 44 | 37 | 38 | 119 |
| Male | 37 | 38 | 38 | 113 |
| Race (NIH/OMB)(Participants) | Placebo | 175mg BIO101 | 350mg BIO101 | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 13 | 13 | 14 | 40 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 3 | 7 | 1 | 11 |
| White | 65 | 55 | 61 | 181 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Placebo | 175mg BIO101 | 350mg BIO101 | Total |
|---|---|---|---|---|
| Belgium | 7 | 6 | 7 | 20 |
| United States | 74 | 69 | 69 | 212 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2017 to primary completion in Apr 2020, 38 months.
Results were first posted in Oct 2024, 4 years 5 months after primary completion.
Of 20 phase 2 interventional studies under Sarcopenia, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 39. This study's 38 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ecdystene
Biophytis